Last reviewed · How we verify

Nonunion of fracture — Treatment Landscape & Competitive Intelligence

Nonunion of fracture (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Nonunion of fracture, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Osigraft EPTOTERMIN ALFA Olympus Biotech International Limited 2001-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Olympus Biotech International Limited · 1 drug in Nonunion of fracture

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Nonunion of fracture:

Cite this brief

Drug Landscape (2026). Nonunion of fracture — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/nonunion-of-fracture. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing